Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany, comments on the molecular diagnostic tools which characterize rare pancreatic cancers, and help in the identification of commonly occurring genomic alterations. Dr Arnold continues highlights, however, that it remains to be seen whether these mutations are truly predictive for directing treatment related to these alterations. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.